Introduction
In 2008, an article published in Cancer Control about adolescents and young adults (AYAs) addressed this emerging, complicated, and multifaceted field. 1 The authors concluded that more data were needed on treatment and survivorship in this patient population to improve outcomes and opined that major academic centers should develop the framework for a specialized oncology discipline focusing on AYAs. 1 Indeed, published research on AYAs has addressed aspects of their care but has not yet successfully improved upon the entirety of oncology specific to AYAs. Programs devoted to AYAs have developed and specialized their focus to address fertility or psychosocial aspects of care, but no single model has yet to be universally adopted or standardized as the gold standard for the care of AYAs with cancer. Difficulties exist when discussing or acknowledging aspects of AYA care, such as reproductive health and sexuality, which was the theme of the annual conference of the Critical Mass Young Adult Alliance in 2015.
Institute as adverse differences in incidence, outcome, or burden of cancer existing among a population group. 3 Although chronological age demarcates oncology in AYAs, it is this emerging developmental period of adulthood that brings in other aspects of disparities. In the context of oncology, AYAs are defined as individuals diagnosed with cancer between 15 and 39 years of age. 4 Cancer is the primary cause of disease-related death in this population. 5 In 2011, an estimated 69,212 AYAs were diagnosed with cancer, equating to 6 times more than children younger than 14 years of age. 6 According to a cancer statistics review of Surveillance, Epidemiology, and End Results program data from 1975 to 1997, improvement in 5-year survival rates, as reflected in the average annual percent change in US cancer mortality rates, was significantly lower among individuals 15 to 39 years of age compared with those aged 1 to 14 years. 4 AYAs have inferior outcomes compared with children and older adults with the same diagnosis. [7] [8] [9] [10] [11] Among younger AYAs aged 15 to 24 years, leukemia, lymphoma, central nervous system tumors, sarcomas, and germ cell tumors are the most common malignancies. 6 In AYAs 25 to 39 years of age, leukemia and lymphoma are still common, but the incidence rates of breast cancer, melanoma, and colorectal cancer (CRC) are increased (Fig) . AYAs may experience economic disparities as they enter the workforce, often in jobs without benefits. 4 In addition, disparities in health education may exist, because AYAs are inexperienced in navigating the health system or inquiring about clinical trials. 4 They also may experience delays in diagnosis, because malignancies are low on the differential diagnosis for ill patients who are young.
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Presentation, Diagnosis, and Access to Health Care
Health Insurance and Financial Hardship
Cancer diagnosis is typically delayed in AYAs compared with children. The cause is multifactorial and relates to low suspicion of a malignant diagnosis by both patient and caretaker, but also is related to inadequate insurance coverage. 4 In the United States, those between the ages of 18 and 24 years and between 25 and 34 years are more likely than any other age group to be uninsured. 13, 14 Lack of health insurance in AYAs is associated with delays in diagnosis, an increased likelihood of metastatic disease at presentation, and a decreased likelihood of receiving definitive therapy compared with those who are insured. [15] [16] [17] [18] In a study of more than 39,000 participants aged 20 to 40 years, health insurance coverage was associated with a decreased likelihood of metastatic disease at presentation; those who were uninsured were more likely to be male, nonwhite, and unmarried. 15 After adjusting for various factors, health insurance coverage was also significantly associated with lower estimates of all-cause mortality. 15 In a study looking at the association between health insurance coverage, socioeconomic status, and the risk of advanced Hodgkin lymphoma in AYAs, public insurance coverage for low-income or individuals with medical need was associated with an increased risk of advanced disease on presentation compared with patients with private insurance.
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Financial hardships are not uncommon in patients with cancer but they may be more burdensome among AYAs. 19 Some AYAs may have introductory level jobs with limited time off and without the ability to take extended leave, have limited savings, and may have college debt. perience negatively affected their financial situation. 19 Financial hardship in relation to the costs of cancer treatment can cause stress, may result in reduced quality of life, and may lead to patients terminating their therapeutic plan. 19 The Affordable Care Act has enabled more than 2.5 million young adults aged 19 to 25 years to gain access to health insurance, although the uninsured rate is still highest among those aged 15 to 39 years.
14,17 After implementation of the Affordable Care Act Dependent Coverage Expansion, detection rates increased for early-stage cervical cancer among women aged 21 to 25 years secondary to increases in access to health care. 20 Diagnosing cervical cancer in its early stage affords the oncologist the possibility of using fertility-sparing treatments; thus, the proportion of young women with cancer able to receive fertility-sparing treatment increased. 20 Further analyses are needed to determine whether expanded coverage for health insurance is associated with other favorable changes in AYAs.
Treatment
The optimal location of care is a complex topic. Expertise for a given cancer diagnosis may lie within either pediatric or medical oncologists. Pathways could provide an optimal range of therapeutic options, identify areas for future clinical research for AYAs, and create disease-specific champions for AYAs passionate about the care of this patient population. Although the treatment protocol may be similar for certain cancers, others may vary with respect to outcomes, cost of care, or intensity of care. 21 It is our opinion that a larger pool of expertise may exist at an adult facility for melanoma or neuroendocrine diseases, but patients with sarcoma most likely receive similar care at both the adult and pediatric cancer centers due to shared staffing. Care for a patient with leukemia must involve increasing levels of collaboration to provide personalized care using an evidence-based approach to treatment. 22 Patients treated in a National Cancer Institute-designated comprehensive cancer center have superior outcomes compared with those treated at facilities not designated as such, a fact likely due to the preponderance of trials conducted at these centers. 18 Barriers impeding access to National Cancer Institute-designated comprehensive cancer centers include lack of health care insurance, public insurance, lower socioeconomic status, and African American or Hispanic race/ethnicity. 22 Approximately 28% of patients older than 15 years of age are treated at community centers, not tertiary care centers. 23 AYAs are the least likely of all age groups to be treated at comprehensive cancer centers and, therefore, they may lack opportunities for multidisciplinary care, tumor board discussions, subspecialty care (eg, rare tumors), and the opportunity to enroll in clinical trials.
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Clinical Trial Enrollment
The percentage of AYAs enrolled in clinical trials is lower than that seen in younger or older patients. 21, [25] [26] [27] [28] [29] AYAs who are uninsured, older in age, or treated by nonpediatric oncologists are less likely than older patients to be enrolled in a clinical trial. 25 Even within institutions that have the same clinical trials, enrollment of AYAs is lower than the enrollment of the pediatric population. 28, 29 Many obstacles contribute to the low number of AYAs enrolled in clinical trials, one of which is lack of knowledge about clinical trials among AYAs. In 1 study, 62% of AYAs did not know if clinical trials were available for their type of cancer. 30 Treatment location is also a factor. A total of 40% of AYAs are treated at academic centers. 31 Even when treated at a cancer center, not all clinical trials are available. Some hospitals are not allowed to enroll patients in Children Oncology Group trials if they are not participating institutions.
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In 2012, the Centers for Disease Control and Prevention convened a group of oncologists who were experts in the AYA population to examine barriers to clinical trial enrollment among adolescents. Five issues were identified as the most important barriers 33 : 1. Low referral rates of adolescents with cancer to pediatric cancer centers 2. Limited availability of clinical trials for certain cancers 3. Physician-related barriers limiting clinical trial accrual 4. Institutional barriers impeding collaboration between pediatric and nonpediatric oncologists on clinical trials 5. Unique psychosocial needs of adolescents with cancer Progress has been made by creating AYA programs at select cancer centers and by increasing the development and availability of clinical trials for AYA patients. 34, 35 Although the number of programs for AYAs with cancer is increasing in the United States, no formal accreditation, registry, or minimal standard exists by which to measure these targeted programs; thus, the structures available and the services offered vary among programs. 36 In an attempt to standardize treatment and services for AYAs with cancer, various organizations have developed treatment guidelines and recommendations for this patient population (Table 1) . 4, [35] [36] [37] [38] [39] [40] In 2016, the National Comprehensive Cancer Network published updated treatment guidelines for AYAs with cancer.
37 Its recommendations emphasize the need for a comprehensive, multidisciplinary approach to AYA care, including supportive and treatment guidelines that aim to improve treatment tolerance, compliance, and clinical outcomes.
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Although dedicated efforts to design programs aimed at increasing clinical trial enrollment in AYAs have shown some promise, improvements are more likely with sustained, systematic approaches to clinical trial research in the AYA population. 41 Efforts to improve trial enrollment are ongoing, some of which use multidisciplinary, collaborative oncology and pediatric specialist teams to study diseases such as leukemia and sarcoma. 38 Clinical trial registries, advocacy groups, and efforts to increase collaborations and communication across adult and pediatric cancer centers are likely to continue progress in increasing clinical trial enrollment rates in AYAs (Table 2) .
Psychosocial Needs and Late Effects
The wide age range of AYA care includes patients still under the guardianship of their parents to those in committed relationships and married; thus, the psychosocial needs among this age group widely vary. Quality of life, adjusting to a cancer diagnosis, searching for meaning or understanding after a diagnosis, and vocational outcomes can be challenging. AYAs may require psychosocial care throughout the cancer care continuum because, if left unaddressed, such psychosocial issues may lead to poorer outcomes than patients with access to age-appropriate resources. During young adulthood, autonomy and self-reliance are prized and contribute to a person's sense of accomplishment and maturity. 42 AYAs with cancer may have experienced these shortly before medical and financial hardships forced them into the care of their parents, away from the working world or from pursuing their education and possibly isolating them from their peers without cancer. 36 This isolation can be reinforced when AYAs see their friends achieving age-specific milestones, such as graduation, career success, marriage, and starting a family, because they may be unable to achieve or experience these same life events while undergoing treatment or recovering in survivorship stages. 43 Because of these experiences, the coordination of cancer care while maintaining social connectivity is paramount to the successful treatment of AYAs. 42 Some of the services AYAs require while undergoing treatment include financial counseling and insurance assistance, pain management, and mental health and peer support (Table 3 ). The need for these services is not exclusive to AYAs with cancer; however, the life stage of AYAs exacerbates these associated needs, particularly because many AYAs report that these needs remain unmet. 44 AYAs have higher rates of distress at diagnosis than older matched populations, and they maintain high rates of distress during survivorship. [45] [46] [47] Smith et al 48 looked at the unmet needs in AYAs and found that patients who lacked mental health services had the poorest health-related quality-of-life scores. AYAs have identified family support, religious beliefs, and personal encouragement as the strongest sources of support during a cancer diagnosis and subsequent treatment. 49 Another study reported that patients who had adequate health care insurance, a good family support system, and were properly informed about preserving their fertility were the most happy with their cancer care. 50 In addition, AYAs who were the most capable of coping with their diagnosis maintained involvement in their career, school, or social spheres. 47 Relationships can shape the lives of AYAs and may be a helpful source of support throughout the cancer care continuum. Significant others or life partners may also play roles in decision-making, potential discourse, and act as support systems. The key caregiver or health care proxy assisting in medical decisions may vary with each AYA, their state of residence, and may not remain consistent throughout the disease trajectory. Research suggests that the most important opinions about the medical care of AYAs may not come from family members, as a clinical care team may assume; instead, AYAs hold opinions of friends and peers in higher regard. 51 Doing so may increase levels of stress or isolate patients in such a way that they feel they are making decisions on their own. 52 Many AYAs are also unsure how or when to share their cancer diagnosis, impaired fertility, and medical debt, among other issues, with a prospective partner. 53 Self-confidence and vulnerability are important aspects of any relationship formation, but many AYAs struggle with negative body issues or low levels of self-esteem, and report that their experience with cancer has negatively affected their developing romantic relationships. [53] [54] [55] AYAs may also feel burdensome to parents, spouses, and siblings, especially if family members make special work arrangements and sacrifices to be more available to patients undergoing treatment.
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Health care professionals have cited end-of-life care as the most difficult need to meet in the AYA population. [57] [58] [59] Several studies have looked at the best time to discuss advanced care planning, suggesting that discussions should begin as early as the initial diagnosis and as late as hospice referral. [60] [61] [62] Research also suggests that AYAs who make their final wishes known regain more control of their health care situation than patients who do not express their wishes. 63, 64 In addition, AYAs who had a written advanced care planning document reported higher rates of active coping and emotional support than those without a written instructions for advanced care planning. 65 One study found that advanced care planning reduced levels of anxiety and familial conflict, because such wishes were discussed in advance and a health care surrogate was identified. 63 Caregivers of AYAs also benefitted from the conversation about end-of-life planning as they were able, in times of great grief, to realize and carry out the wishes of their loved one. 63 Such events would not likely have happened without guidance for advanced care planning.
Some meaningful progress in AYA care has involved the formative and focused research to identify the psychosocial needs of AYAs and the development of programs to help address those needs; similarly, AYA-focused organizations strive to provide financial, vocational, and insurance assistance to cancer patients, survivors, and their friends and families (see Table 3 ). Progress was also made when the American Academy of Pediatrics and the Institute of Medicine established recommendations to include AYAs in their own end-of-life discussions, stating that such discussions did not contradict a hopeful, positive outcome. 61 The creation of Five Wishes (Aging With Dignity, Tallahassee, FL) has allowed health care professionals to use a more age-appropriate advance care planning tool to respect the goals and priorities of AYAs at the end of their life. 61 This tool has also served as a starting point for feedback from AYAs and to continue to develop the most applicable advance care planning for young adults with cancer and the thoughts they wish to convey to their loved ones.
Fertility and Reproductive Health
A significant psychosocial concern among AYA patients is loss of fertility. Chemotherapy, radiotherapy, surgery, and cancer itself can cause temporary or permanent damage to the reproductive organs and endocrine or pituitary functioning. The risk of permanent infertility depends on patient age (younger patients typically fare better than older patients), type of cancer and its treatment, and the dose and intensity of the treatment. 66, 67 In addition, females may experience premature ovarian insufficiency or failure, causing infertility, premature menopause, or both. 67 In the midst of a cancer diagnosis, understanding a patient's risk of infertility and possible options for preserving fertility can be daunting and complex. Decisionmaking about infertility and fertility preservation can be challenging for the AYA patient because multiple barriers exist. [67] [68] [69] [70] [71] [72] A patient may not have considered his or her desire for biological children in the future, and such decisions may become compounded by the stress of a cancer diagnosis. 68 The patient or the oncologist may feel that a delay in treatment to pursue fertility preservation is unwise, and thus the patient may not have time to pursue preservation. 69, 70 The financial costs associated with fertility preservation are often not covered by health care insurance, thus making fertility preservation out of reach for many AYA patients. 67 Ethical, religious, and other matters should be considered and may impede the decision-making of an AYA about fertility preservation. Discussions about fertility and sexual health may be uncomfortable for the AYA patient, particularly if his or her parents are present. Although the parents and loved ones of AYAs with cancer typically want to be helpful and support the patient as much as possible, studies suggest that they may not be appropriate proxy decision-makers about fertility on behalf of AYA patients. 71, 72 It is also worth noting that AYAs with cancer are as sexually active as their peers without cancer. [73] [74] [75] [76] Thus, health care professionals should be aware of intimacy concerns and changes due to treatment and have tactful and meaningful conversations with AYAs about reported adverse events and solutions, if possible. Equally important is for the oncologist to refer AYA patients to contraception counseling, because AYAs have been shown to take more sexual risk, such as not using adequate contraceptive measures. 77, 78 Therefore, contraception should be a key discussion point with patients and their medical team, because some patients may assume they are infertile due to their treatment and think they have no need for contraception for pregnancy purposes or they may engage in unprotected sex to verify the fact that their infertility has been impaired. 79 It is also worth noting that patients receiving active treatment are more susceptible to sexually transmitted infections because their immune systems are compromised. 77, 80 Pregnancy while undergoing cancer treatment can pose risks to the fetus as well as the patient, and making difficult decisions to terminate a pregnancy may cause increased stress and turmoil for a young patient already trying to cope with a cancer diagnosis and treatment.
Discussions of potential threats to fertility with all patients of childbearing age with newly diagnosed cancer are recommended by several medical organizations, including as the American Society of Clinical Oncology, 40 the National Comprehensive Cancer Network, 68 and the American Society for Reproductive Medicine.
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In addition to discussion about the potential impact of treatment or cancer type on fertility, the American Society of Clinical Oncology and other resources recommend that AYA patients be referred to a reproductive endocrinologist or infertility specialist to discuss options for fertility preservation as soon as possible after a diagnosis of cancer is received and prior to the start of treatment (see Table 1 ). 4, [35] [36] [37] [38] [39] [40] The established fertility preservation methods are sperm cryopreservation for postpubertal males and oocyte and embryo cryopreservation for postpubertal females as well as ovarian transposition for patients undergoing pelvic or abdominal radiotherapy.
37, 40 For prepubertal children, fertility preservation options are experimental and include testicular or ovarian tissue cryopreservation. 40 Studies suggest that patients who do not learn about potential threats to their fertility may experience feelings of remorse and regret during the survivorship period. [82] [83] [84] Although few patients (particularly females) opt to use fertility-preservation methods, most patients report satisfaction and appreciation for learning about this information from their health care professional.
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Progress of Cancer Biology
Though many common diagnoses afflicting the AYA population overlap with those seen in younger and older patients, new data have emerged showing differences in disease biology by age. 8, 87, 88 Acute lymphoblastic leukemia (ALL) is the most common malignancy and leading cause of cancer-related deaths in AYAs. 88 Outcomes of AYAs treated for ALL are worse for those aged 10 years or older. 8, 88 The treatment varies: In adult-based protocols, transplants are more common, whereas pediatric-based protocols call for intensive therapy, including asparaginase, and do not rely as heavily on transplants. [89] [90] [91] [92] A difference exists in the frequency of cytogenetic abnormalities that predispose AYAs to worse outcomes, but it may also serve as a target for improved therapy. 8, 10, 93, 94 Opportunities for improved outcomes may also exist in Philadelphia chromosome-positive ALL when tyrosine kinase inhibitors are added to treatment (Table 4) . [7] [8] [9] [10] 88, [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] A large prospective trial of 296 patients aged 16 to 39 years demonstrated that treatment with an intensive pediatric regimen showed significant rates of improvement in event-free survival (66%) and overall survival (78%) along with manageable toxicities. 89, 90 Other trials have shown superior outcomes in AYAs treated in pediatric protocols. 89 Such ongoing collaborations with cooperative groups may lead to uniform treatment based on biology, with age being one among many other variables.
Sarcoma is a common type of cancer in AYAs. [103] [104] [105] [106] [107] Overall, these mesenchymal-derived malignancies of the soft tissue and bone represent 8% of new diagnoses in patients aged 15 to 39 years. 108 Standard chemotherapies for front-line regimens for osteosarcoma, rhabdomyosarcoma, and Ewing sarcoma have been established through cooperative group studies. [103] [104] [105] [106] [107] In these studies, pediatric patients typically comprise the majority of the groups. Standard therapies for other soft-tissue sarcomas have been primarily derived from studies of adult populations, in whom these diagnoses are more common. 109, 110 Oftentimes, no clear consensus exists regarding systemic therapies for metastatic, relapsed, or recurrent disease.
108 Some retrospective reviews of single-institution experiences and cooperative group studies explore the presentation, biology, and therapeutic variables and how they generally negatively impact the outcomes of AYA patients compared with younger patients (see Table 4 ). [7] [8] [9] [10] 88, [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [111] [112] [113] Effort has been made to collaborate through the adultand pediatric-focused cooperative groups and may serve as a model for future trials. 38 Breast cancer has an age-related biological difference that dictates outcomes. 99, 100, 114, 115 Breast cancer is one of the most frequently diagnosed malignancies among women aged 15 to 39 years and makes up 14% of all cancers diagnosed in AYAs. 9 Nearly 7% of all breast cancers are diagnosed in women younger than 40 years of age. 8, 99 AYAs have a higher incident rate of more aggressive phenotypes, such as triple-negative breast cancer, ERBB2 (formerly known as HER2/neu)-overexpressing cancers, and luminal B cancers. 9, 99, 100, 114, 115 A low proportion of AYAs present with luminal A disease, which confers a better prognosis. 100 In addition, a higher proportion of AYAs present with stage III/IV disease. 99 AYA pa- tients with breast cancer have a high prevalence of BRCA1/BRCA2 mutations. 9, 99, 100, 114, 115 CRC is another example of the biological and genetic differences seen in AYAs compared with older adults. The AYA population has high incidence rates of microsatellite instability and heritable forms of CRC such as familial adenomatous polyposis and hereditary nonpolyposis colon cancer. 10 It may also be true that the disease biology of young patients with CRC but without inherited syndromes may differ from the type of CRC seen in older adults. 10 Overall, compared with older patients, AYAs present with more advanced-stage disease at diagnosis and more aggressive tumor features. 116 Melanoma can affect individuals at any age, but it is more common in adults than children. 87 Its basic disease biology -numerous mutations and a preponderance of BRAF V600E mutations -appears to hold true across all ages. 117 Metastases to sentinel lymph nodes occur more frequently in children and AYAs than in adults with the same stage of disease. 88 With the approval of ipilimumab, nivolumab, and other inhibitors and combination therapies, we question whether AYAs were adequately represented and enrolled in recent successful trials. 118 Based on the biology of melanoma, similar treatment outcomes are expected in the AYA population.
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Remaining Challenges
The management of cancer in AYA patients is a continuous process that has experienced progress in recent years. We now understand more about what AYA patients need and are poised to learn even more about possible approaches to improve many aspects of AYA care. However, doing so requires future research that emphasizes the biological differences in certain diseases to develop targeted treatments for this population.
Lack of health insurance among this age group is still a major concern because being uninsured can potentially delay diagnosis and access to treatment as well as to the possibility of inhibiting any transition to surveillance and life-long survivorship care. A large study looking at the unmet needs of AYA patients reported that 50% of AYA participants had unmet information needs about cancer recurrence, cancer treatments, and long-term adverse events, and up to 50% of AYA patients had unmet information needs on fertility, nutrition, and financial support. 44 
Conclusions
Adolescent and young adult (AYA) patients face disparities based on age that can lead to a delay in diagnosis, an advanced stage of disease at presentation, suboptimal treatment location, lack of clinical trial availability, and an increased burden of quality survivorship through the loss of fertility or disruption in social, personal, or financial growth and stability. These disparities in AYAs have inspired individuals and institutions to develop programs designed for AYAs to meet the specific or overall health care needs of this patient population. In addition, some organizations have advocated for AYA cancer care as a specific discipline within oncology; to improve fertility education and access to preservation; to address the root causes of the lack of survival improvement; and to define the essential elements of care for this population. Today we understand more about what AYA patients need, and we are poised to learn even more about approaches to improve many aspects of care for these patients. We are optimistic that motivated patients, health care professionals, advocacy organizations, and institutions will align to develop improved models for the care of AYAs.
